Bayer CropScience 配当と自社株買い
配当金 基準チェック /46
Bayer CropScience配当を支払う会社であり、現在の利回りは3.58%です。
主要情報
3.6%
配当利回り
n/a
バイバック利回り
| 総株主利回り | n/a |
| 将来の配当利回り | 3.8% |
| 配当成長 | 19.6% |
| 次回配当支払日 | n/a |
| 配当落ち日 | n/a |
| 一株当たり配当金 | n/a |
| 配当性向 | 98% |
最近の配当と自社株買いの更新
Recent updates
ナラティブの更新 • Jun 23
506285: Dividend Strength And Compostable Nursery Initiative Will Support Upside Potential
The analyst price target for Bayer CropScience has been modestly adjusted to ₹5,186.83 from ₹5,163. This reflects updated views on a slightly higher profit margin outlook, a revised discount rate and a recalibrated future P/E assumption.ナラティブの更新 • Jun 05
506285: Dividend Outlook And Updated Assumptions Will Support A Positive Future
Analysts have adjusted their price target for Bayer CropScience slightly lower from ₹5,209.63 to ₹5,163.00, citing updated assumptions around the discount rate, revenue growth, profit margin and future P/E. What's in the News Bayer CropScience has scheduled a Board Meeting for May 26, 2026, to consider and record the audited financial results for the quarter and financial year ended March 31, 2026, and to consider a recommendation for a final dividend for the 2025-26 financial year, if any.ナラティブの更新 • May 01
506285: Stable Assumptions And Upcoming Results Will Shape A Balanced Outlook
Analysts have maintained their fair value estimate for Bayer CropScience at ₹5,209.63 per share, making only minor adjustments to assumptions such as discount rate, revenue growth, profit margin and future P/E. This suggests that their overall view on the stock's long-term potential remains broadly unchanged.ナラティブの更新 • Apr 17
506285: Upcoming Results And Refined Assumptions Will Support A Balanced Outlook
The analyst price target for Bayer CropScience has been adjusted slightly higher to ₹5,209.63 from ₹5,187.13. Analysts point to updated fair value estimates, a modest change in the assumed discount rate, and revised expectations for revenue, profit margins, and future P/E as key inputs behind this move.ナラティブの更新 • Apr 02
506285: Upcoming Results And Stable Assumptions Will Support A Balanced Outlook
Analysts have kept their price target on Bayer CropScience broadly unchanged around ₹5,187. This reflects only marginal model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their core view.ナラティブの更新 • Mar 19
506285: Upcoming Results And Stable Assumptions Will Support A Positive Outlook
Analysts have marginally revised their price target for Bayer CropScience to ₹5,187, reflecting small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, rather than any major shift in the outlook. What's in the News A board meeting is scheduled for February 11, 2026, to review and consider the unaudited financial results for the quarter ended December 31, 2025 (Key Developments).ナラティブの更新 • Mar 04
506285: Sustainability Partnership And Upcoming Results Will Support A Positive Outlook
Analysts have kept their price target for Bayer CropScience broadly unchanged around ₹5,187, citing only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially alter their overall view on the stock. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).ナラティブの更新 • Feb 17
506285: Sustainability Collaboration And Upcoming Results Will Support A Balanced Outlook
Analysts have trimmed their price target for Bayer CropScience to ₹5,187 from about ₹5,278, reflecting updated views on slightly lower fair value, a modestly adjusted discount rate, marginally different margin expectations and a revised future P/E assumption, while keeping revenue growth assumptions largely supportive. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).ナラティブの更新 • Feb 03
506285: Expanded Sustainability Partnership Will Support Bullish Outlook Into Next Year
Analysts have kept their fair value estimate for Bayer CropScience effectively unchanged at €5,277.67, with only marginal tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects steady underlying expectations rather than a shift in view.ナラティブの更新 • Jan 20
506285: Farmer Focused Sustainability Partnership Will Support Bullish Outlook Into Next Year
Analysts have slightly reduced their fair value estimate for Bayer CropScience to about €5,278. This reflects modest tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, without a major shift in the overall thesis.ナラティブの更新 • Jan 05
506285: Interim Dividend Decision Will Support Bullish Outlook Into Next Year
Analysts have kept their fair value estimate for Bayer CropScience steady, with only marginal tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions guiding a largely unchanged price target narrative. What's in the News A board meeting is scheduled for November 7, 2025, to review the unaudited financial results for the quarter ended September 30, 2025.ナラティブの更新 • Dec 21
506285: Interim Dividend Decision Will Drive Bullish Momentum Into Next Year
Analysts have modestly raised their price target on Bayer CropScience by about €5, citing a slightly higher long term discount rate and valuation assumptions that leave fair value largely unchanged. What's in the News Board meeting scheduled for November 7, 2025, to review unaudited financial results for the quarter ended September 30, 2025 (Key Developments) Board to consider declaration of an interim dividend for the financial year 2025 to 2026 at the November 7, 2025 meeting (Key Developments) Record date for the proposed interim dividend to be fixed during the upcoming board meeting (Key Developments) Valuation Changes The discount rate has risen slightly from 13.34% to 13.35%, reflecting a marginally higher required return on equity.ナラティブの更新 • Dec 07
506285: Interim Dividend Decision Will Drive Bullish Sentiment Into 2025
Narrative Update on Bayer CropScience Analysts have trimmed their price target for Bayer CropScience by approximately EUR 275, reflecting slightly softer expectations for revenue growth and profit margins, even as long term valuation multiples remain supportive. What's in the News A board meeting is scheduled for November 7, 2025 to review the unaudited financial results for the quarter ended September 30, 2025.ナラティブの更新 • Nov 23
506285: Interim Dividend Consideration Will Drive Bullish Momentum Into 2025
Narrative Update on Bayer CropScience Analysts have lowered their fair value estimate for Bayer CropScience from €5,939 to €5,556. They attribute this reduction to a slightly lower projected profit margin, which outweighs improvements in expected revenue growth and a modest decrease in the discount rate.新しいナラティブ • May 18
Seeds, Traits And Biofuels Will Unlock New Value Pools
Strategic cost reductions and efficiency improvements are expected to enhance net margins and unlock substantial additional cash.決済の安定と成長
配当データの取得
安定した配当: 506285の配当金支払いは、過去10年間 変動性 が高かった。
増加する配当: 506285の配当金は過去10年間にわたって増加しています。
配当利回り対市場
| Bayer CropScience 配当利回り対市場 |
|---|
| セグメント | 配当利回り |
|---|---|
| 会社 (506285) | 3.6% |
| 市場下位25% (IN) | 0.3% |
| 市場トップ25% (IN) | 1.5% |
| 業界平均 (Chemicals) | 0.8% |
| アナリスト予想 (506285) (最長3年) | 3.8% |
注目すべき配当: 506285の配当金 ( 3.58% ) はIndian市場の配当金支払者の下位 25% ( 0.29% ) よりも高くなっています。
高配当: 506285の配当金 ( 3.58% ) はIndian市場 ( 1.48% ) の配当支払者の中で上位 25% に入っています。
株主への利益配当
収益カバレッジ: 506285は高い 配当性向 ( 97.8% ) のため、配当金の支払いは利益によって十分にカバーされていません。
株主配当金
キャッシュフローカバレッジ: 506285は合理的な 現金配当性向 ( 66.5% ) を備えているため、配当金の支払いはキャッシュフローによって賄われます。
高配当企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/27 01:30 |
| 終値 | 2026/06/25 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2026/03/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Bayer CropScience Limited 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。24
| アナリスト | 機関 |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| Himanshu Binani | Anand Rathi Shares and Stock Brokers Limited |
| null null | Anand Rathi Shares and Stock Brokers Limited |